Autoimmune Diseases Working Party

Chair: John Snowden
Secretary: Tobias Alexander
Study Coordinator: Manuela Badoglio

Number of HSCT for autoimmune diseases: 2899
EBMT Registry - February 2019

Transplant procedures
- Autologous HSCT
  - for myelodysplastic syndrome
  - for myeloma
  - for lymphoma
  - for acute leukaemia

Number of patients undergoing autologous HSCT
- Patients: 2899
- Male/Female %: 49/51
- Paediatric/Adult %: 15/85
- Centre Countries: 287/41
- Overall follow-up (median, 10 HSCT ± 2017): 3y (1-23)

Major achievements
- The ADWP continues to expand the evidence-base and established the field with both registry-based studies and guidelines written with disease specialist.
- Autoimmune diseases (ADs) are now the fastest growing indication for HSCT (Passweg et al, 2018), reflecting a significant change in transplant practice over the 20 years of evolution and the active role of the ADWP continues to play in bringing together active EBMT centres and disease specialist communities.
- The ADWP section of the EBMT registry is the now the largest database of its kind worldwide with almost 3,000 transplants currently reported. Special consideration has been given to the future EBMT registry developments in order to accommodate the needs of the multispeciality interactions for sustainable long-term data collection in patients with ADs undergoing HSCT and other cell therapies.
- Education continues to be central to the ADWP activities with multiple educational meetings globally. In November 2018, the ADWP educational meeting, organised jointly in Florence with SAAWP, attracted the greatest number of delegates ever reflecting growing interest in the field by both transplant haematologists and disease specialists. The ADWP will repeat the event in Berlin on 31 October - 1 November 2019.
- The ADWP is also fully engaged in other EBMT activities, including the E-learning portal, the EBMT Curriculum and the EBMT Handbook. There has also been productive interaction with the EBMT Nurses Group and Patient, Family and Donor Committee.
- “Implementation science” is now needed to define how best to deliver HSCT in the context of biological and other modern therapies for AD. The future will depend on safety and quality of care, including refinement of transplant techniques. Therefore the ADWP continues to work closely with JACIE and disease specialist groups to assure best practice and quality of outcomes.

Recent key publications
- Autologous HSCT for Crohn’s Disease: A Retrospective Survey of Long-term Outcomes from the EBMT, Brierley CK, J Crohns Colitis. 2018 May 18
- General information for patients and carers considering HSCT for severe ADs: A position statement from the ADWP EBMT, the EBMT Nurses Group, the EBMT Patient, Family and Donor Committee and the Joint Accreditation Committee of ISCT and EBMT (JACIE). H Jessop, Bone Marrow Transplant. 2019 Jan 31.